Drug intelligence / Profile preview

FURMENT HepaCor

Development stage: Unknown
Lead developer: Sirius Pet Biologics
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

FURMENT HepaCor is a postbiotic supplement developed by Sirius Pet Biologics specifically for hepatic support in dogs and cats. Utilizing proprietary Miiiome Technology, the product contains a fermented blend of *Lactobacillus* species (postbiotics) designed to modulate the pet's gut microbiome. It is intended to promote liver health, assist in liver detoxification, and improve overall digestive function by addressing dysbiosis. The supplement is administered orally, typically as a capsule or as a powder mixed with food, and is marketed toward both veterinary clinics and the retail pet health market.

Brand names: FURMENT HepaCor
Other names: HepaCorFURMENT HepaCor Postbiotics

Beyond the preview

Go deeper on FURMENT HepaCor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FURMENT HepaCor.

Explore the full profile